Abstract: The present invention provides for nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (NFAH) or non-nanostructured or pre-nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (FAH), as hemostatic agents designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. These hydrogels can be applied topically to the wound either on the skin in a laparotomy or as non-invasive manner in surgical procedures. Its nanostructure technology generates an adhesive stable fibrin clot required for hemostasis. The attachment properties of the hydrogel, as well as the rapid formation of a fibrin clot, ensures that a strong stable fibrin clot is formed shortly after application.

Abstract: The invention relates to an aqueous melatonin composition exhibiting surprising long-term stability and allowing high concentrations of said water-insoluble active ingredient. The properties of said composition render it useful as an injectable, for example, for the intravenous administration thereof.

Abstract: The invention describes a method for predicting or prognosticating the risk of death or vasospasm in a patient with a subarachnoid hemorrhage, which comprises the following steps: performing a clinical assessment of the patient according to the Hunt and Hess scale and the World Federation of Neurosurgeons (WFNS) scale; obtaining a computerised axial tomography image of the patient's skull; normalising the image obtained according to a standard skull template; obtaining a region corresponding to intracranial blood by segmenting the normalised image; calculating at least the following parameters of the region of cranial blood obtained: total volume, fractal dimension and surface-volume ratio; and determining the probability of death or vasospasm in the patient according to at least the parameters calculated.

Abstract: The invention refers to a composition comprising inactivated cells deficient in LPS from the genus Acinetobacter and/or outer membrane vesicles form the same and their use for the manufacture of a medicament, preferably a vaccine, for the prevention of diseases produced by organisms of the genus Acinetobacter.

Abstract: The present invention provides a method for identifying epithelial cells circulating in peripheral blood, which allows individuals who suffer from a disease that presents with epithelial cell destruction to be discriminated from those who do not. The invention also relates to a kit or device for carrying out the methods of the invention.

Abstract: The invention relates to a wave-emitting device comprising an electromechanical actuator stimulated by a signal generator that allows it to generate torsional waves with a higher amplitude, and to an ultrasonic transducer comprising said device. The use of said devices allows the reconstruction of the structural characteristics of the materials subject to the waves generated by the emitter device.

Abstract: The invention refers to a composition comprising inactivated cells deficient in LPS from the genus Acinetobacter and/or outer membrane vesicles form the same and their use for the manufacture of a medicament, preferably a vaccine, for the prevention of diseases produced by organisms of the genus Acinetobacter.

Abstract: A tool coupling includes a first tool part and a second tool part, the second tool part being movable in relation to the first tool part. The tool coupling further includes a first base part for detachably retaining the first tool part and a second base part movable in relation to the first base part for detachably retaining the second tool part. The first base part has a pusher movable in relation to the first base part for detaching the first tool part and the second base part has a cap movable in relation to the second base part for detaching the second tool part.

Abstract: The invention relates to compositions used to relieve, improve, prevent and/or treat stretch marks and/or skin ulcers preferably of ischemic origin. The invention also relates to the composition, dosage form and uses thereof.

Abstract: The present invention refers to a cell suspension of autologous or allogeneic, preferably autologous, adult bone marrow-derived white blood cells, preferably derived from the crest of the ilium (or iliac crest), enriched for mononuclear cells, meaning more than 25% of the white blood cells (WBCs) present in the cell suspension are mononuclear cells, and comprising: A. Mononuclear cells (MNC) selected from the list comprising or consisting of: i. A population of Lymphocytes; ii. A population of Monocytes; and iii. A population of Hematopoietic stem cells expressing CD34; and wherein the cell suspension further comprises: B. Granulocytes; for use in the treatment or amelioration of lower extremity peripheral artery disease.

Abstract: The invention relates to a novel open retinoscope comprising: a body (3) comprising a light source (31) oriented in the longitudinal direction and a first coupling means (32) for coupling to a Volk lens (51) holder in a longitudinally sliding manner; a Volk lens (51) holder (5), coupled in a longitudinally sliding manner to the body (3), where the holder (5) comprises a second longitudinal sliding coupling means (52) which is complementary to the first longitudinal sliding coupling means (32) of the body (3); and a smartphone adaptor (2) which can be connected to the body (3) in a transversely sliding manner.

Abstract: The invention relates to a method for obtaining useful data about the angiogenesis in a patient's lower limbs, and particularly in the lower limbs of patients with diabetes subjected to treatment.

Abstract: Use of the non-peptide NK1 receptor antagonist, preferably Aprepitant, for the treatment of cancer in predetermined doses. The present invention also describes pharmaceutical compositions comprising said agents, alone or in combination with at least one other active principle, for the treatment of cancer.

Abstract: The present invention relates to a composition comprising a neurokinin-1 receptor antagonist and at least one excipient selected from an oil, a fatty acid or a polyol, as well as to an administration form for administering a formulation, wherein said administration form is selected from: inhalant, nebulization, vapor, smoke or aerosol and comprises said composition. In addition, the invention relates to said composition for use as medicament, said administration form for use as medicament, preferably said composition for use as medicament in the treatment of at least one disease of the respiratory tract, or said administration form for use as medicament in the treatment of at least one disease of the respiratory tract. Moreover, the invention also provides methods for producing said composition and said administration form, as well as a kit of parts comprising said composition and an administration device.

Abstract: A tool coupling includes a first tool part and a second tool part, the second tool part being movable in relation to the first tool part. The tool coupling further includes a first base part for detachably retaining the first tool part and a second base part movable in relation to the first base part for detachably retaining the second tool part. The first base part has a pusher movable in relation to the first base part for detaching the first tool part and the second base part has a cap movable in relation to the second base part for detaching the second tool part.

Abstract: The invention relates to a method for the diagnosis of liver fibrosis, comprising detecting the level of expression of the gene GATA-4, or the quantity of the protein GATA-4, in the isolated biological sample of liver tissue. The invention also relates to a diagnosis kit.

Abstract: The invention refers to a composition comprising inactivated cells deficient in LPS from the genus Acinetobacter and/or outer membrane vesicles form the same and their use for the manufacture of a medicament, preferably a vaccine, for the prevention of diseases produced by organisms of the genus Acinetobacter.

Abstract: The invention relates to the field of oncology and cancer treatment. The invention relates to methods for predicting the risk of recurrence of breast tumors using the expression signature of particular miRNAs. Specifically, the invention relates to a method for determining the risk of recurrence of breast cancer which comprises measuring the expression levels of at least one miRNA selected from the group consisting of miR-149-5p (SEQ ID NO: 1), miR-10a-5p, (SEQ ID NO: 2), miR-20b-5p, (SEQ ID NO: 3), miR-30a-3p (SEQ ID NO: 4), and miR-342-5p, (SEQ ID NO: 5) in a sample of the tumor, wherein a change in the expression level of at least one miRNA in the tumor with respect to the expression level in a control sample is indicative of a high risk of recurrence of the tumor. The invention also relates to tools and kits for carrying out the method of the invention.

Abstract: The present invention relates to the use of compounds of a cannabinoid nature for inhibiting viability with increasing doses of myeloma cell lines. Furthermore, said compounds have been shown not to affect CD34+ cells (normal hematopoietic progenitors) in terms of viability and proliferation. For this reason, the invention paves the way for the use of compounds of a cannabinoid nature as a promising therapy against multiple myeloma and related diseases.

Abstract: The invention relates to a novel open retinoscope comprising: a body (3) comprising a light source (31) oriented in the longitudinal direction and a first coupling means (32) for coupling to a Volk lens (51) holder in a longitudinally sliding manner; a Volk lens (51) holder (5), coupled in a longitudinally sliding manner to the body (3), where the holder (5) comprises a second longitudinal sliding coupling means (52) which is complementary to the first longitudinal sliding coupling means (32) of the body (3); and a smartphone adaptor (2) which can be connected to the body (3) in a transversely sliding manner.